GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Artivion Inc (NYSE:AORT) » Definitions » Return-on-Tangible-Equity

Artivion (Artivion) Return-on-Tangible-Equity : 0.00% (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Artivion Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Artivion's annualized net income for the quarter that ended in Dec. 2023 was $-15.9 Mil. Artivion's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $-140.4 Mil. Therefore, Artivion's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was N/A%.

The historical rank and industry rank for Artivion's Return-on-Tangible-Equity or its related term are showing as below:

During the past 13 years, Artivion's highest Return-on-Tangible-Equity was 11.46%. The lowest was 0.00%. And the median was 6.44%.

AORT's Return-on-Tangible-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.97
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Artivion Return-on-Tangible-Equity Historical Data

The historical data trend for Artivion's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artivion Return-on-Tangible-Equity Chart

Artivion Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Tangible Equity - - - -

Artivion Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Tangible Equity - - - -

Competitive Comparison of Artivion's Return-on-Tangible-Equity

For the Medical Devices subindustry, Artivion's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artivion's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Artivion's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Artivion's Return-on-Tangible-Equity falls into.



Artivion Return-on-Tangible-Equity Calculation

Artivion's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-30.69/( (-141.949+-137.788 )/ 2 )
=-30.69/-139.8685
=N/A %

Artivion's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-15.9/( (-143.034+-137.788)/ 2 )
=-15.9/-140.411
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Artivion  (NYSE:AORT) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Artivion Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Artivion's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Artivion (Artivion) Business Description

Traded in Other Exchanges
Address
1655 Roberts Boulevard North West, Kennesaw, GA, USA, 30144
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
Executives
Jean F Holloway officer: VP, General Counsel C/O ARTIVION INC, 1655 ROBERTS BLVD, KENNESAW GA 30144
John E Davis officer: Senior VP, Global Sales 1655 ROBERTS BLVD., NW, KENNESAW GA 30144
Amy Horton officer: Chief Accounting Officer C/O CRYOLIFE, INC., 1655 ROBERTS BLVD., NW, KENNESAW GA 30144
Florian Tyrs officer: VP, Global Operations IM SOELLER 3, BALINGEN 2M 72336
Robert C Thomson officer: VP Research & Development 33 HABERSHAM COVE DRIVE, NW, ATLANTA GA 30305
Matthew A Getz officer: VP, Human Resources 1655 ROBERTS BLVD NW, KENNESAW GA 30144
Dennis B Maier officer: Vice President, Operations 1655 ROBERTS BLVD, NW, KENNESAW GA 30144
Rochelle L. Maney officer: VP, Quality 1655 ROBERTS BLVD, NW, KENNESAW GA 30144
James P Mackin officer: President & CEO ARTIVION, INC., 1655 ROBERTS BLVD, NW, KENNESAW GA 30144
Marshall S. Stanton officer: SVP, Clinical & MD Affair 1655 ROBERTS BLVD, NW, KENNESAW GA 30144
Andrew M Green officer: VP Regulatory ARTIVION INC, 1655 ROBERTS BLVD, KENNESAW GA 30144
David Ashley Lee officer: Executive VP, COO & CFO C/O CRYOLIFE INC, 1655 ROBERTS BLVD NW, KENNESAW GA 30144
Elizabeth A Hoff director 2701 WESTHEIMER ROAD, UNIT 1-E, HOUSTON TX 77098
Anthony B. Semedo director 3288 HARRISON GRADE ROAD, SEBASTOPOL CA 95472
Ronald D Mccall director C/O CRYOLIFE, INC., 1655 ROBERTS BOULEVARD, NW, KENNESAW GA 30144